Relmada Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Relmada Therapeutics reported cash, cash equivalents, and short-term investments of $202.1 million at the end of the 3rd quarter of 2026, compared with $93 million at December 31st, 2025.
- Research and development expense for the 3 months ended September 30th, 2026 was $9.2 million, compared with $4 million for the 3 months ended September 30th, 2025, primarily reflecting higher NDB-01 and cepranolone study preparation costs, manufacturing and drug storage costs, and employee compensation, partially offset by lower stock-based compensation.
- General and administrative expense for the 3 months ended September 30th, 2026 was $3.9 million, compared with $6.3 million for the same period last year.
- Net cash used in operating activities for the 3 months ended September 30th, 2026 was $12.6 million, compared with $6.7 million for the 3 months ended September 30th, 2025.
- The 3rd quarter 2026 net loss was $13.9 million, or $0.12 per basic and diluted share, compared with a net loss of $10.1 million, or $0.30 per basic and diluted share, for the 3rd quarter of 2025.
- In the NDB-01 Phase 2 long-term extension, 12 of 14 evaluable patients, or 86%, remained in complete response (CR) at 18 months; in the BCG unresponsive subgroup, 7 of 8 patients, or 88%, remained in CR.
- Two BCG-naive patients progressed to muscle invasive disease at month 15, and no patients in the study had undergone radical cystectomy to date.
- Updated 12-month results among 51 high-risk NMIBC patients showed an anytime CR rate of 94% and a 12-month CR rate of 77%; in the BCG unresponsive subgroup, the rates were 96% and 73%, respectively.
- The Phase 2 study had no grade 3 or higher treatment-related adverse events, treatment-related serious adverse events, or treatment-related discontinuations.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and welcome to the Relmada Therapeutics Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the prepared remarks, we will conduct a question-and-answer session. To ask a question, please press star one. As a reminder, this conference call is being recorded and will be available for replay on the Relmada website. I would now like to turn the call over to Brian Ritchie from LifeSci Advisors. Please go ahead, Mr. Ritchie.
Good day, everyone, and thank you for joining us today. This afternoon, Relmada issued a press release providing a business update and outlining its financial results for the three and nine months ended September 30th, 2026. Please note that certain information discussed on the call today is covered under the Safe Harbor provision of the Private Securities Litigation Reform Act. Relmada's management team will be making forward-looking statements during this call. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Relmada's press release issued today and the company's SEC filings, including the company's 10-Q filing for the quarter ended September 30th, 2026, filed after the close today.
This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast on November 12th, 2026. Relmada undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. With me today on today's call are Relmada CEO, Dr. Sergio Traversa, Dr. Bipin Dalmia, Relmada's Chief Business Officer, and Relmada CFO, Maged Shenouda. After the prepared remarks, we will open the call for a brief Q&A session. Now, I would like to hand the call over to Sergio Traversa.
Sergio? Thank you, Brian. Good afternoon, everyone, and welcome to the Relmada Third Quarter 2026 Conference Call.
We have made significant progress with the NDV-01 program in the third quarter, and during today's call, I will provide the business overview, including an update on manufacturing. Bipin will review the 18-month phase II results, which continue to demonstrate durability of response and a favorable safety profile, as well as the phase III registrational program, now renamed SPECTRUM, to reflect NDV-01's potential across the full spectrum of non-muscle invasive bladder cancer, NMIBC. Maged will then review the third quarter financial results, and then I will come back to make a few concluding remarks. Let's start with NDV-01. NDV-01 is a novel sustained-release intravesical formulation that combines gemcitabine and docetaxel with the potential for quick and convenient administration in the urology office.
In the quarter, we have made significant progress in the manufacturing process, and we are on track to submit the IND by year-end 2026. The IND clearance will allow us to begin our registrational trials, marking an important step forward in the approval process for NDV-01. Beyond the IND filings, we have established a manufacturing plan to provide uninterrupted clinical supply through phase III and support commercial readiness. Turning to sepranolone, our program for Prader-Willi syndrome, we are finalizing the stability testing of our prefilled syringe to enable IND submission, which is anticipated by year-end 2026. We expect to begin the phase II proof-of-concept study upon IND clearance. We will now give Bipin the privilege to take through the 18-month data and the phase III program for NDV-01.
Bipin. Thank you, Sergio, and good afternoon, everyone.
For bladder-sparing therapies in non-muscle invasive bladder cancer, or NMIBC, patients and physicians are still forced to trade off efficacy, durability, tolerability, and convenience. We believe NDV-01 has the potential to deliver on all those dimensions simultaneously, and importantly, with a ready-to-use product that is designed for ease of market adoption and broad utilization. The data we are reporting today reinforce that view. Let me start with the initial 18-month phase II results for NDV-01. In NMIBC, durability of response is a key question, and our long-term extension is where it gets answered. 23 high-risk NMIBC patients who are in complete response, or CR, at 12 months continued into a long-term extension study. Of the 14 evaluable patients at 18 months, 12, or 86%, remain in CR.
In the BCG unresponsive subgroup, seven of eight patients, or 88%, remain in CR at 18 months. Two patients progressed to muscle-invasive disease at month 15, one BCG-naive T1 patient and a second BCG-naive CIS with T1 patient. No patients in the study have undergone a radical cystectomy to date. We also updated our 12-month results, which now include 51 high-risk NMIBC patients. As the dataset has grown, the results have remained consistent, with anytime CR rate of 94% and a 12-month CR rate of 77%. In the BCG unresponsive subgroup, where the need for effective bladder-sparing options is the greatest, the anytime CR rate was 96% and the 12-month CR rate was 73%. Just as important, these efficacy results come with a consistently favorable safety and tolerability profile.
In the phase II study to date, there have been no grade 3 or higher treatment-related adverse events, no treatment-related serious adverse events, and no treatment-related discontinuations. Our market research shows that for a therapy designed for repeated in-office administration, including in the community setting where most patients are treated, such a clean safety and tolerability profile matters. Turning to our registrational phase III program. As Sergio noted, we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the entire NMIBC disease spectrum. Importantly, the program itself remains unchanged, with two FDA-aligned, independent registrational pathways. The first is a single-arm registrational study in second-line, high-risk BCG unresponsive NMIBC patients with carcinoma in situ, or CIS, with or without papillary disease. In addition, we have a separate exploratory cohort in second-line, high-risk BCG unresponsive papillary-only disease.
The second is a randomized study of NDV-01 as adjuvant therapy following TURBT versus observation in low-grade, intermediate-risk NMIBC, a setting with no approved therapies currently. To sum up, we believe the larger and more mature phase II data continue to support NDV-01's potential to uniquely combine high and durable responses, a favorable safety and tolerability profile, with a simple in-office administration of a ready-to-use, sustained-release, biodegradable product, the combination physicians tell us they need. We look forward to initiating the phase III SPECTRUM program upon IND clearance. With that, I will turn the call over to Maged.
Maged? Thanks, Bipin, and good afternoon, everyone.
I'd like to build on Sergio and Bipin's comments by highlighting the substantial progress in manufacturing that should enable us to file the INDs for NDV-01 and sepranolone by year-end. We're also encouraged by the continued durability of response of the 18-month data that positions NDV-01 competitively and has the potential to make a meaningful difference in patient lives. I'll now walk you through our third quarter 2026 financial results. Our press release and 10-Q filing provide the full details, including the nine-month results. Relmada closed the third quarter of 2026 with cash equivalents, and short-term investments of $202.1 million, compared to $93 million at December 31, 2025. Our current cash position is expected to fund company operations through 2029, including completion of the registrational phase III NDV-01 SPECTRUM studies. Moving briefly through our third quarter financial results.
Research and development expense for the three months ended September 30, 2026, totaled $9.2 million, compared to $4 million for the three months ended September 30, 2025. The increase was primarily attributable to higher NDV-01 and sepranolone study preparation costs, increased manufacturing and drug storage costs, and higher employee compensation, partially offset by lower stock-based compensation. General and administrative expense for the same period totaled $3.9 million, compared to $6.3 million for the same period last year. The decrease was primarily driven by lower stock-based compensation and lower stock appreciation rights expense, partially offset by higher employee compensation and consulting services. Net cash used in operating activities for the three months ended September 30, 2026, totaled $12.6 million, compared to $6.7 million for the three months ended September 30, 2025.
The net loss for the quarter was $13.9 million, or $0.12 per basic and diluted share, compared with a net loss of $10.1 million, or $0.30 per basic and diluted share for the third quarter of 2025. Before we open the call for questions, I'll turn back to Sergio for some closing comments.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
